Pharma's Market
SPECIAL REPORT
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Garlic Price Rises Surpass Gold, Stocks in China
- Oil Price to Average $75.40 in 2010: Poll
- Obama Reiterates Commitment to Boost US-India Ties
- Half of Banks' Losses May Still Be Hidden: IMF Head
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Jobless Claims Below 500,000, Durable Orders Slip
- Americans Ditch Planes for Trains this Thanksgiving
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
- Schork Oil Outlook: Gas Bulls Pinning Hopes on Mother Nature
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Consumer Mood Improves, But Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- Garlic Price Rises Surpass Gold, Stocks in China
- Judge Erases Couple's $525,000 Mortgage Payment
- Obama Going to Copenhagen Climate Summit
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Seeking Deals, Holiday Fliers Get Early Start
- Americans Ditch Planes for Trains this Thanksgiving
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
PHARMA'S MARKET VIDEO
RSS FEED
Text Size 
CNBC Correspondent
 |
Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.
Presumably with more people being covered, big pharma could make up in volume what it might lose on government-negotiated price.
But now that the House has passed a bill Wall Street seems to be treating that theory like a sudden revelation. The AMEX pharmaceutical index and, in fact, all of the big pharma stocks, both foreign and domestic are higher. Novartis [NVS
Loading...
()
] hit a new high. And Merck [MRK
Loading...
()
] is getting an assist from an upgrade to the equivalent of “Buy” with a $38 target at Leerink Swann.
Analyst Seamus (Shay-mus) Fernandez actually put out two research notes to clients on MRK today. One is about the upgrade and the other is about the Zetia vs. Niaspan study that’s coming out in “The New England Journal of Medicine” and at the American Heart Association meeting at, according to Fernandez, 11:07 a.m. ET next Monday. Regarding the stock Fernandez writes, “We believe near-term concerns may offer liquidity opportunities to build, or add to, a position in MRK.”
One of those near-term concerns is the drug study called Arbiter 6. I know it sounds more like the name of a NASA space program, but there it is. Zetia is a stand-alone cholesterol-fighting drug owned by Merck and it’s also used in the company’s combo pill Vytorin (Zocor is the other ingredient.) Abbott Labs [ABT
Loading...
()
] makes Niaspan. Leerink Swann, which specializes in healthcare stocks, did a survey of more than a hundred docs: 31 cardiologists and 72 primary care physicians. A majority of the docs thinks Niaspan is the winner of the head-to-head battle. And if that’s true, the survey says Zetia/Vytorin prescriptions could fall 25-35 percent over a 12-month period. If that happens, Fernandez estimates Zetia/Vytorin sales could fall between $600 million and $900 million and that Merck’s earnings per share could take a 20-cent hit.
So, I guess on the one hand Fernandez is telling investors to brace themselves and, on the other, to be ready to buy MRK on the potential weakness. I’ll be reporting live from the AHA meeting in Orlando a week from today.
Update: The AHA says the embargo will lift on the Arbiter 6 data at 8 a.m. ET next Monday. I'm sure the companies appreciate the results not coming out during the trading day, so this will give analysts/investors a good hour-and-a-half to digest the data before the opening bell.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes